Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (15 quarters reported)
$70.5M in Q4 2015 → $120M now. Hover for any quarter.
As reported for the quarter ended June 30, 2019. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Intercept Pharmaceuticals Inc | 10.1% | Added 1175% | 152,441 | $12.1M |
| Insmed Inc | 10.0% | Added 66% | 470,741 | $12.1M |
| AT Audentes Therapeutics Inc | 9.3% | Added 17% | 294,013 | $11.1M |
| Neurocrine Biosciences Inc | 6.5% | Added 284% | 92,380 | $7.8M |
| Sarepta Therapeutics Inc | 6.4% | Added 137% | 50,317 | $7.65M |
| GB Global Blood Therapeutics Inc | 6.2% | Added 63% | 142,305 | $7.49M |
| I Immunomedics Inc | 6.1% | Added 57% | 524,140 | $7.27M |
| CB Coherus Biosciences Inc | 5.8% | New | 316,316 | $6.99M |
| Ascendis Pharma A/s | 5.8% | New | 60,266 | $6.94M |
| Pacira Biosciences Inc | 5.4% | New | 149,086 | $6.48M |
| Urogen Pharma Ltd | 5.3% | Added 33% | 176,866 | $6.36M |
| UN Uniqure Nv | 3.9% | Added 54% | 59,883 | $4.68M |
| Amarin Corp PLC | 3.7% | Added 55% | 230,295 | $4.47M |
| Abbvie Inc | 3.2% | New | 52,681 | $3.83M |
| BP Biohaven Pharmaceutical Holdin | 3.1% | New | 86,165 | $3.77M |
| MN Mylan Nv | 1.6% | New | 102,560 | $1.95M |
| IT Intra-cellular Therapies Inc | 1.6% | New | 143,665 | $1.87M |
| Regeneron Pharmaceuticals Inc | 1.5% | New | 5,668 | $1.77M |
| Madrigal Pharmaceuticals Inc | 1.3% | Added 347% | 15,423 | $1.62M |
| D Dermira Inc | 1.1% | New | 138,102 | $1.32M |
| Gilead Sciences Inc | 1.1% | New | 18,697 | $1.26M |
| Anaptysbio Inc | 0.6% | New | 12,026 | $679K |
| AP Allergan PLC | 0.5% | Trimmed 76% | 3,347 | $560K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2019 · filed August 14, 2019
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Intercept Pharmaceuticals Inc | Added | +140,489 | +$11.2M | 10.1% |
| Heron Therapeutics Inc | Exited | −388,623 | −$9.5M | — |
| CB Coherus Biosciences Inc | New | +316,316 | +$6.99M | 5.8% |
| Ascendis Pharma A/s | New | +60,266 | +$6.94M | 5.8% |
| Pacira Biosciences Inc | New | +149,086 | +$6.48M | 5.4% |
| Neurocrine Biosciences Inc | Added | +68,340 | +$5.77M | 6.5% |
| BH Bausch Health Cos Inc | Exited | −205,660 | −$5.08M | — |
| Insmed Inc | Added | +186,478 | +$4.77M | 10.0% |
| Sarepta Therapeutics Inc | Added | +29,047 | +$4.41M | 6.4% |
| ST Stemline Therapeutics Inc | Exited | −325,526 | −$4.18M | — |
Showing the 10 largest of 35 changes.
quarter ended March 31, 2019 · filed May 15, 2019
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR S&P Biotech ETF | Exited | −499,200 | −$35.8M | — |
| Biomarin Pharmaceutical Inc | Exited | −341,400 | −$29.1M | — |
| Teva Pharmaceutical Industries | Exited | −1,683,500 | −$26M | — |
| Novartis Ag | Trimmed | −270,788 | −$22.9M | 4.7% |
| AT Audentes Therapeutics Inc | Trimmed | −513,573 | −$20M | 11.9% |
| Insmed Inc | Trimmed | −554,683 | −$16.1M | 10.0% |
| BH Bausch Health Cos Inc | Trimmed | −459,177 | −$11.3M | 6.2% |
| I Immunomedics Inc | Trimmed | −559,955 | −$10.8M | 7.8% |
| Heron Therapeutics Inc | Trimmed | −430,541 | −$10.5M | 11.5% |
| HP Horizon Pharma PLC | Exited | −396,198 | −$7.74M | — |
Showing the 10 largest of 35 changes.
quarter ended December 31, 2018 · filed February 14, 2019
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR S&P Biotech ETF | Trimmed | −500,800 | −$35.9M | 14.8% |
| AP Allergan PLC | Exited | −158,712 | −$30.2M | — |
| Exelixis Inc | Trimmed | −1,427,291 | −$28.1M | 2.5% |
| Novartis Ag | New | +316,117 | +$27.1M | 11.2% |
| Teva Pharmaceutical Industries | New | +1,683,500 | +$26M | 10.7% |
| MN Mylan Nv | Exited | −695,788 | −$25.5M | — |
| DP Dova Pharmaceuticals Inc | Exited | −1,026,906 | −$21.5M | — |
| Heron Therapeutics Inc | Added | +729,315 | +$18.9M | 8.8% |
| CT Cara Therapeutics Inc | Exited | −737,303 | −$17.7M | — |
| GB Global Blood Therapeutics Inc | Trimmed | −327,569 | −$13.4M | 3.8% |
Showing the 10 largest of 60 changes.
quarter ended September 30, 2018 · filed November 14, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR S&P Biotech ETF | Trimmed | −1,000,000 | −$95.9M | 18.4% |
| T Tesaro Inc | Exited | −433,500 | −$19.3M | — |
| PP Pacira Pharmaceuticals Inc/de | Exited | −566,508 | −$18.2M | — |
| AP Alexion Pharmaceuticals Inc | Exited | −132,623 | −$16.5M | — |
| Cellectis Sa | Exited | −548,212 | −$15.5M | — |
| Sangamo Therapeutics Inc | Exited | −1,066,914 | −$15.2M | — |
| BH Bausch Health Cos Inc | New | +545,500 | +$14M | 2.7% |
| Astrazeneca PLC | Trimmed | −327,000 | −$12.9M | 1.5% |
| Sage Therapeutics Inc | Exited | −79,080 | −$12.4M | — |
| AP Allergan PLC | Trimmed | −63,401 | −$12.1M | 5.8% |
Showing the 10 largest of 70 changes.
quarter ended June 30, 2018 · filed August 14, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Exelixis Inc | New | +1,421,600 | +$30.6M | 4.7% |
| Bristol-myers Squibb Co | Exited | −342,399 | −$21.7M | — |
| Biomarin Pharmaceutical Inc | Exited | −259,235 | −$21M | — |
| SP Shire PLC | Exited | −139,543 | −$20.8M | — |
| T Tesaro Inc | New | +433,500 | +$19.3M | 3.0% |
| Biomarin Pharmaceutical Inc | Added | +192,300 | +$18.1M | 4.4% |
| SG Seattle Genetics Inc | Trimmed | −260,787 | −$17.3M | 1.1% |
| AP Alexion Pharmaceuticals Inc | New | +132,623 | +$16.5M | 2.5% |
| CO Clovis Oncology Inc | Exited | −242,600 | −$12.8M | — |
| Heron Therapeutics Inc | Exited | −409,000 | −$11.3M | — |
Showing the 10 largest of 57 changes.
quarter ended March 31, 2018 · filed May 15, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Bristol-myers Squibb Co | New | +342,399 | +$21.7M | 3.6% |
| Merck & Co Inc | Exited | −346,293 | −$19.5M | — |
| SG Seattle Genetics Inc | New | +362,974 | +$19M | 3.1% |
| Bristol-myers Squibb Co | Exited | −295,600 | −$18.1M | — |
| Corcept Therapeutics Inc | New | +1,045,196 | +$17.2M | 2.8% |
| Astrazeneca PLC | New | +484,000 | +$16.9M | 2.8% |
| Astrazeneca PLC | Exited | −466,600 | −$16.2M | — |
| AN Ablynx Nv | Exited | −637,884 | −$15.9M | — |
| PP Pacira Pharmaceuticals Inc/de | New | +478,620 | +$14.9M | 2.5% |
| FT Flexion Therapeutics Inc | Exited | −466,500 | −$11.7M | — |
Showing the 10 largest of 60 changes.
quarter ended December 31, 2017 · filed February 14, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR S&P Biotech ETF | Added | +500,000 | +$42.4M | 31.3% |
| AP Allergan PLC | New | +207,871 | +$34M | 6.3% |
| SG Seattle Genetics Inc | Exited | −373,000 | −$20.3M | — |
| MN Mylan Nv | New | +470,296 | +$19.9M | 3.7% |
| Merck & Co Inc | New | +346,293 | +$19.5M | 3.6% |
| Bristol-myers Squibb Co | New | +295,600 | +$18.1M | 3.3% |
| Teva Pharmaceutical Industries | Exited | −1,000,000 | −$17.6M | — |
| Astrazeneca PLC | New | +466,600 | +$16.2M | 3.0% |
| AN Ablynx Nv | New | +637,884 | +$15.9M | 2.9% |
| CO Clovis Oncology Inc | Exited | −184,680 | −$15.2M | — |
Showing the 10 largest of 58 changes.
quarter ended September 30, 2017 · filed November 14, 2017
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR S&P Biotech ETF | New | +1,500,000 | +$130M | 33.4% |
| SG Seattle Genetics Inc | New | +373,000 | +$20.3M | 5.2% |
| Teva Pharmaceutical Industries | New | +1,000,000 | +$17.6M | 4.5% |
| Astrazeneca PLC | Exited | −490,000 | −$16.7M | — |
| CO Clovis Oncology Inc | New | +184,680 | +$15.2M | 3.9% |
| C Celgene Corp | Exited | −99,110 | −$12.9M | — |
| Pfizer Inc | Exited | −350,030 | −$11.8M | — |
| Sangamo Therapeutics Inc | New | +781,000 | +$11.7M | 3.0% |
| F Fibrogen Inc | New | +217,329 | +$11.7M | 3.0% |
| KP Kite Pharma Inc | Exited | −110,000 | −$11.4M | — |
Showing the 10 largest of 58 changes.
Loading...
